|
1
|
Lu L, Xue X, Lan J, et al: MicroRNA-29a
upregulates MMP2 in oral squamous cell carcinoma to promote cancer
invasion and anti-apoptosis. Biomed Pharmacother. 68:13–19. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sharma P, Saxena S and Aggarwal P: Trends
in the epidemiology of oral squamous cell carcinoma in Western UP:
an institutional study. Indian J Dent Res. 21:316–319. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rautava J, Luukkaa M, Heikinheimo K, Alin
J, Grenman R and Happonen RP: Squamous cell carcinomas arising from
different types of oral epithelia differ in their tumor and patient
characteristics and survival. Oral Oncol. 43:911–919. 2007.
View Article : Google Scholar
|
|
4
|
Peng CH, Liao CT, Peng SC, et al: A novel
molecular signature identified by systems genetics approach
predicts prognosis in oral squamous cell carcinoma. PLoS One.
6:e234522011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen R, Yang K, Zhao NB, et al: Abnormal
expression of PER1 circadian-clock gene in oral squamous
cell carcinoma. Onco Targets Ther. 5:403–407. 2012.
|
|
6
|
Angell JE, Lindner DJ, Shapiro PS, Hofmann
ER and Kalvakolanu DV: Identification of GRIM-19, a novel cell
death-regulatory gene induced by the interferon-β and retinoic acid
combination, using a genetic approach. J Biol Chem.
275:33416–33426. 2000.PubMed/NCBI
|
|
7
|
Wen LJ, Gao LF, Jin CS, et al: Small
interfering RNA survivin and GRIM-19 co-expression salmonella
plasmid inhibited the growth of laryngeal cancer cells in vitro and
in vivo. Int J Clin Exp Pathol. 6:2071–2081. 2013.PubMed/NCBI
|
|
8
|
Nallar SC, Kalakonda S, Lindner DJ, et al:
Tumor-derived mutations in the gene associated with retinoid
interferon-induced mortality (GRIM-19) disrupt its anti-signal
transducer and activator of transcription 3 (STAT3) activity and
promote oncogenesis. J Biol Chem. 288:7930–7941. 2013. View Article : Google Scholar
|
|
9
|
Alchanati I, Nallar SC, Sun P, et al: A
proteomic analysis reveals the loss of expression of the cell death
regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene.
25:7138–7147. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fusco A, Viglietto G and Santoro M: Point
mutation in GRIM-19: a new genetic lesion in Hurthle cell
thyroid carcinomas. Br J Cancer. 92:1817–1818. 2005.
|
|
11
|
Maximo V, Botelho T, Capela J, et al:
Somatic and germline mutation in GRIM-19, a dual function
gene involved in mitochondrial metabolism and cell death, is linked
to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J
Cancer. 92:1892–1898. 2005.PubMed/NCBI
|
|
12
|
Zhou Y, Li M, Wei Y, et al:
Down-regulation of GRIM-19 expression is associated with
hyperactivation of STAT3-induced gene expression and tumor growth
in human cervical cancers. J Interferon Cytokine Res. 29:695–703.
2009.
|
|
13
|
Zhang L, Gao L, Li Y, et al: Effects of
plasmid-based Stat3- specific short hairpin RNA and GRIM-19 on
PC-3M tumor cell growth. Clin Cancer Res. 14:559–568. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hao H, Liu J, Liu G, et al: Depletion of
GRIM-19 accelerates hepatocellular carcinoma invasion via inducing
EMT and loss of contact inhibition. J Cell Physiol. 227:1212–1219.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Okamoto T, Inozume T, Mitsui H, et al:
Overexpression of GRIM-19 in cancer cells suppresses STAT3-mediated
signal transduction and cancer growth. Mol Cancer Ther.
9:2333–2343. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang T, Yan XB, Zhao JJ, et al: Gene
associated with retinoid-interferon-induced mortality-19 suppresses
growth of lung adenocarcinoma tumor in vitro and in vivo. Lung
Cancer. 72:287–293. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kalvakolanu DV: The GRIMs: a new interface
between cell death regulation and interferon/retinoid induced
growth suppression. Cytokine Growth Factor Rev. 15:169–194. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lufei C, Ma J, Huang G, et al: GRIM-19, a
death-regulatory gene product, suppresses Stat3 activity via
functional interaction. EMBO J. 22:1325–1335. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Turkson J: STAT proteins as novel targets
for cancer drug discovery. Expert Opin Ther Targets. 8:409–422.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Niu G, Wright KL, Huang M, et al:
Constitutive Stat3 activity up-regulates VEGF expression and tumor
angiogenesis. Oncogene. 21:2000–2008. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie TX, Wei D, Liu M, et al: Stat3
activation regulates the expression of matrix metalloproteinase-2
and tumor invasion and metastasis. Oncogene. 23:3550–3560. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sobin LH and Wittekind CH: UICC TNM
Classification of Malignant Tumors. 7th edition. Springer-Verlag;
Berlin: 2010
|
|
23
|
Hamilton SR and Aaltonen LA: Pathology and
Genetics Tumours of the Digestive System. 3rd edition. IARC Press;
Lyon: 2000
|
|
24
|
Zhang H, Li Z and Wang K: Combining
sorafenib with celecoxib synergistically inhibits tumor growth of
non-small cell lung cancer cells in vitro and in
vivo. Oncol Rep. 31:1954–1960. 2014.
|
|
25
|
Gao L, Zhang L, Hu J, et al:
Down-regulation of signal transducer and activator of transcription
3 expression using vector-based small interfering RNAs suppresses
growth of human prostate tumor in vivo. Clin Cancer Res.
11:6333–6341. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thompson CB: Apoptosis in the pathogenesis
and treatment of disease. Science. 267:1456–1462. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
|
|
30
|
Ribatti D and Vacca A: The role of
microenvironment in tumor angiogenesis. Genes Nutr. 3:29–34. 2008.
View Article : Google Scholar
|
|
31
|
MacDougall JR and Matrisian LM:
Contributions of tumor and stromal matrix metalloproteinases to
tumor progression, invasion and metastasis. Cancer Metastasis Rev.
14:351–362. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fullar A, Kovalszky I, Bitsche M, et al:
Tumor cell and carcinoma-associated fibroblast interaction
regulates matrix metalloproteinases and their inhibitors in oral
squamous cell carcinoma. Exp Cell Res. 318:1517–1527. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bjorklund M and Koivunen E:
Gelatinase-mediated migration and invasion of cancer cells. Biochim
Biophys Acta. 1755:37–69. 2005.PubMed/NCBI
|
|
34
|
Darnell JE Jr: STATs and gene regulation.
Science. 277:1630–1635. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lu Y, Fukuyama S, Yoshida R, et al: Loss
of SOCS3 gene expression converts STAT3 function from
anti-apoptotic to pro-apoptotic. J Biol Chem. 281:36683–36690.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bromberg JF, Wrzeszczynska MH, Devgan G,
et al: Stat3 as an oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar
|
|
37
|
Macha MA, Matta A, Kaur J, et al:
Prognostic significance of nuclear pSTAT3 in oral cancer. Head
Neck. 33:482–489. 2011. View Article : Google Scholar : PubMed/NCBI
|
